---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-22-013267"
form_type: "8-K"
ticker: "OPRX"
cik: "0001448431"
company_name: "OptimizeRx Corp"
filed_at: "2022-03-17T23:59:59+00:00"
generated_at: "2026-06-26T21:58:03.733718+00:00"
event_type: "m_and_a"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# OptimizeRx acquires EvinceMed assets for $2M cash and up to 240,741 shares

## Summary
- Asset purchase of EvinceMed Corp.; total consideration includes $2M cash and up to 240,741 common shares.
- 185,185 shares issued at closing; 55,556 held back for 12 months for indemnification adjustments.
- Closing expected in Q2 2022; shares issued under Section 4(a)(2) exemption.
- Acquisition strengthens OptimizeRx's product offering in patient engagement technology.

## SEC filing metadata
- accession: 0001213900-22-013267
- form_type: 8-K
- ticker: OPRX
- cik: 0001448431
- company_name: OptimizeRx Corp
- filed_at: 2022-03-17T23:59:59+00:00
- event_type: m_and_a
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 3.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1448431/000121390022013267/0001213900-22-013267-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1448431/000121390022013267/ea157011-8k_optimizerx.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-22-013267
- JSON: https://secwatch.observer/filing/0001213900-22-013267.json
- Plain text: https://secwatch.observer/filing/0001213900-22-013267.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.